Home > Insider Trading > Filing (0000905718-18-000518)

Filing Details

Accession Number:: 0000905718-18-000518
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-05-15 20:04:42
Reporting Period:: 2018-05-11

Accepted Time:: 2018-05-15 20:04:42
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1674416	Crispr Therapeutics Ag	CRSP	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1252524	Von Kurt Emster	C/O Crispr Therapeutics, Inc. 610 Main Street Cambridge MA 02139		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Disposition	2018-05-11	113,477	$53.36	1,773,725	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2018-05-11	127,890	$52.46	1,645,835	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2018-05-11	8,633	$51.73	1,637,202	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2018-05-14	116,247	$56.90	1,520,955	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2018-05-14	73,144	$55.72	1,447,811	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2018-05-14	126,901	$54.99	1,320,910	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2018-05-14	53,927	$53.86	1,266,983	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2018-05-14	20,881	$52.93	1,246,102	No	4	S	Indirect	See Footnote
Common Shares	Disposition	2018-05-14	8,900	$52.20	1,237,202	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI LP's ("ABV VI") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG ("Issuer") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's ("ABE") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar).
Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.
From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.95 to $53.94 per share, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.95 to $52.94 per share, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.45 to $51.94 per share, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.38 to $57.37 per share, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.37 to $56.37 per share, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.39 to $55.37 per share, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.38 to $54.37 per share, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.38 to $53.37 per share, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.37 per share, inclusive.
The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.